Medical technology company Carl Zeiss Meditec started financial year 2011/2012 (end of reporting period 31.12.2011) with growth of 13.5 percent. The company generated revenue of EUR 210.3 million in the first quarter (previous year: € 185.2 million). Earnings before interest and taxes (EBIT) increased to 28.3 million euros (previous year: 24.0 million euros).
"I am delighted that we have continued on our solid growth course, in spite of the volatile environment," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.
This growth helped the company to further expand its profitability. The EBIT margin increased to 13.4 percent (previous year: 13.0 percent).
Carl Zeiss Meditec has a broad business portfolio, ranging from ophthalmology, through microsurgery, to new applications in radiation therapy. "The growth we have achieved is testimony to the stable position this puts us in: we once again increased our revenue in all strategic business units and all reporting regions," says Monz.
Key figures at a glance
Both the "Microsurgery" and "Surgical Ophthalmology" strategic business units contributed to this revenue increase, each achieving growth of 23.3 percent. The strategic business unit "Ophthalmic Systems" grew by 2.8 percent.
All of Carl Zeiss Meditec's reporting regions developed positively. Revenue in the "EMEA" region increased by 18.6 percent, in spite of the euro crisis, driven in particular by business transactions in Eastern Europe. A positive effect was also made by the first-time consolidation of the acquired business of IMEX in Spain.
Growing by 14.9 percent, the "Asia/Pacific" region re-affirmed our intensified business efforts in the dynamically developing countries of this region. China, in particular, as well as the countries of Southeast Asia, continued to exhibit strong growth. Development in Japan also continued to be positive.
Revenue in the "Americas" region grew by 7.8 percent. The USA continued to develop positively, with South America once again contributing double-digit growth.
Looking to the future with optimism
The broad business model and the global presence of Carl Zeiss Meditec are helping the company to make a positive development forecast for the long term. With its company programme, Meditec Excellence and Growth Agenda (MEGA) 2015, it is focusing on the following success factors: innovation, customer focus, new markets, a strong team and process excellence. "Particularly in view of the current imponderables concerning the global economy, I feel that our strategy equips Carl Zeiss Meditec AG well for the challenges ahead," says Monz. "We are therefore looking to the future with new determination and shall do everything in our power to continue on our road to success."
Revenue by strategic business unit
Figures in
EUR '000 | 3 Months 2010/2011 | 3 Months 2011/2012 | Change from previous year |
| Ophthalmic Systems | 88,200 | 90,700 | 2.8% |
| Surgical Ophthalmology | 19,731 | 24,325 | 23.3% |
| Microsurgery | 77,313 | 95,316 | 23.3% |
Revenue by region
Figures in
EUR '000 | 3 Months 2010/2011 | 3 Months 2011/2012 | Change from previous year |
| EMEA | 63,460 | 75,271 | 18.6% |
| Americas | 68,527 | 73,897 | 7.8% |
| Asia/Pacific region | 53,257 | 61,173 | 14.9% |
Henriette Meyer, Director Investor Relations, Carl Zeiss Meditec AG Phone: +49 36 41 220-106, Email: investors@meditec.zeiss.com
